MCID: BCT002
MIFTS: 52

Bacterial Vaginosis

Categories: Reproductive diseases

Aliases & Classifications for Bacterial Vaginosis

MalaCards integrated aliases for Bacterial Vaginosis:

Name: Bacterial Vaginosis 12 74 54 3 15 62 17 71
Vaginosis, Bacterial 43

Classifications:



External Ids:

Disease Ontology 12 DOID:3385
MeSH 43 D016585
NCIt 49 C116973
SNOMED-CT 67 85569008
UMLS 71 C0085166

Summaries for Bacterial Vaginosis

PubMed Health : 62 About bacterial vaginosis: In bacterial vaginosis (sometime abbreviated as BV) much larger numbers of bacteria grow inside of the vagina than would normally just be there. This increase in bacteria is usually not dangerous and it often goes unnoticed, but it can cause a strong-smelling vaginal discharge and be very unpleasant. It also increases the risk of a vaginal infection. Antibiotics can provide effective treatment.

MalaCards based summary : Bacterial Vaginosis, also known as vaginosis, bacterial, is related to vaginal discharge and trichomoniasis. An important gene associated with Bacterial Vaginosis is LAP3 (Leucine Aminopeptidase 3), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Norethindrone and Cranberry have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and bone, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A vaginitis that is characterized by a grayish vaginal discharge usually of foul odor and the presence of Gardnerella vaginalis.

CDC : 3 Bacterial vaginosis (BV) is a condition that happens when there is too much of certain bacteria in the vagina. This changes the normal balance of bacteria in the vagina.

Wikipedia : 74 Bacterial vaginosis (BV) is a disease of the vagina caused by excessive growth of bacteria. Common... more...

Related Diseases for Bacterial Vaginosis

Diseases related to Bacterial Vaginosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 526)
# Related Disease Score Top Affiliating Genes
1 vaginal discharge 33.5 LAP3 IL6 CXCL8
2 trichomoniasis 31.9 TNF LAP3 IL6 CXCL8
3 vaginitis 31.9 TNF TLR4 TLR2 LAP3 IL6 IL1B
4 placenta disease 31.2 TNF IL6 IL1B CXCL8
5 endometritis 31.2 TNF TLR4 TLR2 IL6 IL1B CXCL8
6 cervicitis 31.1 TLR4 TLR2 IL6 DEFB4A CXCL8
7 vulvovaginal candidiasis 31.0 TLR2 MBL2 LAP3 DEFB4A DEFA5
8 cystitis 30.7 TNF TLR4 IL6 CXCL8
9 cellulitis 30.7 TNF IL6 IL10 DEFB4A
10 anogenital venereal wart 30.6 TLR9 TLR4 TLR2
11 human immunodeficiency virus infectious disease 30.6 TNF TLR9 MBL2 IL10
12 acute cystitis 30.5 TNF TLR4 TLR2 IL6 IL10 CXCL8
13 chorioamnionitis 30.5 TNF TLR4 MMP8 IL6 IL1B IL1A
14 cytomegalovirus infection 30.5 TNF IL6 IL1B CXCL8
15 chlamydia 30.4 TNF TLR9 TLR4 TLR2 MBL2 IL6
16 scabies 30.4 MBL2 IL1A IL10 CXCL8
17 exanthem 30.4 TNF IL6 IL10 CXCL8
18 amebiasis 30.4 TNF TLR4 TLR2 CXCL8
19 acquired immunodeficiency syndrome 30.3 TNF IL6 IL1B IL10
20 rheumatic disease 30.3 TNF MBL2 IL1B IL10
21 genital herpes 30.3 TLR2 PI3 IL10
22 diarrhea 30.2 TNF TLR4 IL6 IL1B IL10 CXCL8
23 funisitis 30.2 MMP8 IL6 IL1B IL10 CXCL8
24 candidiasis 30.0 TNF TLR4 TLR2 MBL2 LTF IL6
25 pre-eclampsia 29.9 TNF TLR4 IL6 IL1B IL10 CXCL8
26 cervical cancer 29.9 TNF TLR9 TLR4 IL6 IL1A IL10
27 urethritis 29.8 TNF TLR4 TLR2 IL6 DEFB4A DEFA5
28 preterm premature rupture of the membranes 29.8 TNF TLR4 TLR2 MMP8 IL6 IL1B
29 pyelonephritis 29.8 TNF TLR4 MBL2 IL6 IL1B IL10
30 cerebral palsy 29.7 TNF TLR4 MMP8 MBL2 IL6 IL1B
31 toxic shock syndrome 29.6 TNF TLR4 TLR2 IL6 IL1B IL10
32 peritonitis 29.6 TNF TLR4 TLR2 MMP8 IL6 IL1B
33 allergic hypersensitivity disease 29.6 TNF TLR9 TLR4 TLR2 IL10 CXCL8
34 oral candidiasis 29.4 LTF IL1A DEFB4A DEFA1 CXCL8
35 osteoporosis 29.4 TNF TLR4 MMP8 IL6 IL1B IL1A
36 diabetes mellitus 29.4 TNF TLR4 TLR2 IL6 IL1B IL1A
37 vaginal disease 29.2 TNF TLR9 TLR4 TLR2 IL6 IL1B
38 reactive arthritis 28.9 TNF TLR4 TLR2 MMP8 LTF IL6
39 periodontitis 28.8 TNF TLR4 TLR2 MMP8 IL6 IL1B
40 cystic fibrosis 28.3 TNF TLR4 PI3 MBL2 LTF IL6
41 lung disease 28.0 TNF TLR9 TLR4 TLR2 PI3 MMP8
42 bacterial infectious disease 27.7 TNF TLR9 TLR4 TLR2 PI3 MBL2
43 pelvic inflammatory disease 10.9
44 overgrowth syndrome 10.8
45 syphilis 10.7
46 cervix uteri carcinoma in situ 10.6
47 cervical intraepithelial neoplasia 10.6
48 external pathological resorption 10.6 TNF IL6
49 systemic onset juvenile idiopathic arthritis 10.6 TNF IL1B
50 punctate inner choroidopathy 10.6 TNF IL10

Graphical network of the top 20 diseases related to Bacterial Vaginosis:



Diseases related to Bacterial Vaginosis

Symptoms & Phenotypes for Bacterial Vaginosis

MGI Mouse Phenotypes related to Bacterial Vaginosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 IL10 IL1A IL1B IL6 LTF MBL2
2 homeostasis/metabolism MP:0005376 10.17 IL10 IL1A IL1B IL6 LTF MBL2
3 immune system MP:0005387 10.13 IL10 IL1A IL1B IL6 LAP3 LTF
4 cardiovascular system MP:0005385 10.1 IL10 IL1A IL1B IL6 NEU1 PEPD
5 integument MP:0010771 9.85 IL10 IL1A IL1B IL6 NEU1 PEPD
6 liver/biliary system MP:0005370 9.56 IL10 IL6 LTF NEU1 PRF1 TLR2
7 neoplasm MP:0002006 9.32 IL10 IL1A IL1B IL6 LTF MMP8

Drugs & Therapeutics for Bacterial Vaginosis

PubMed Health treatment related to Bacterial Vaginosis: 62

Symptomatic bacterial vaginosis is usually treated using antibiotics to kill the germs . Treatments are available in tablet form or as a suppository or cream for direct application. Another treatment option is suppositories or capsules containing living lactic acid bacteria . These treatments are designed to protect the vaginal flora and restore the correct balance . There is not yet enough evidence on the benefits of this method. Some women also try things like putting tampons that have been soaked in tea tree oil or natural yogurt in their vagina to create a more acidic environment for the vaginal flora, but there has not yet been any research about how effective or safe these kinds of home remedies are.

Drugs for Bacterial Vaginosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 166)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norethindrone Approved Phase 4 68-22-4 6230
2 Cranberry Approved, Investigational Phase 4
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
5
Desogestrel Approved Phase 4 54024-22-5 40973
6
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
7
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
8
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005
9
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
10
Secnidazole Approved Phase 4 3366-95-8
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Metronidazole Approved Phase 4 443-48-1 4173
14
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
15
Norethindrone enanthate Experimental Phase 4 3836-23-5
16 Norethindrone Acetate Phase 4
17 Alkylating Agents Phase 4
18 Immune Sera Phase 4
19 Immunologic Factors Phase 4
20 Cytochrome P-450 CYP3A Inhibitors Phase 4
21 Cytochrome P-450 Enzyme Inhibitors Phase 4
22 Antifungal Agents Phase 4
23 Steroid Synthesis Inhibitors Phase 4
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
25 Antiviral Agents Phase 4
26 Antioxidants Phase 4
27 Free Radical Scavengers Phase 4
28 N-monoacetylcystine Phase 4
29 Respiratory System Agents Phase 4
30 Protective Agents Phase 4
31 Antidotes Phase 4
32 Expectorants Phase 4
33 Antitubercular Agents Phase 4
34 Contraceptives, Oral Phase 4
35 Caproate Phase 4
36 Ortho Evra Phase 4
37 Contraceptives, Oral, Combined Phase 4
38 Hormone Antagonists Phase 4
39 Hormones Phase 4
40 Hawthorn Phase 4
41 Estrogens Phase 4
42 Estradiol 17 beta-cypionate Phase 4
43 Estradiol 3-benzoate Phase 4
44 Estrogens, Conjugated (USP) Phase 4
45 Contraceptive Agents Phase 4
46
Formaldehyde Approved, Vet_approved Phase 3 50-00-0 712
47
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
49
Nitrofurantoin Approved, Vet_approved Phase 3 67-20-9 5353830
50
Dequalinium Approved, Investigational Phase 3 6707-58-0

Interventional clinical trials:

(show top 50) (show all 211)
# Name Status NCT ID Phase Drugs
1 Randomised Control Trial of Probiotics Versus Placebo as Adjuvant to Oral Clindamycin Treatment for Bacterial Vaginosis During Pregnancy Unknown status NCT01558388 Phase 4 Lactobacillus acidophilus;Placebo
2 The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the Treatment of Bacterial Vaginosis Unknown status NCT03080740 Phase 4 Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
3 Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
4 Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda Unknown status NCT02905890 Phase 4 Norethisterone enantate
5 The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4 Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
6 A Double-blind,Randomized,Parallel,Placebo-controlled Study of Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy Unknown status NCT01779193 Phase 4
7 Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole. Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
8 A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis Completed NCT02392026 Phase 4 Metronidazole Gel
9 Tinidazole for the Treatment of Bacterial Vaginosis Completed NCT00334633 Phase 4 tinidazole, metronidazole
10 Extended Antimicrobial Treatment of Bacterial Vaginosis Combined With Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses Completed NCT01245322 Phase 4 lactobacilli
11 Therapy and Prevention for Sexually Associated Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
12 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
13 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding Completed NCT00464542 Phase 4 Metronidazole
14 Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity Completed NCT02445989 Phase 4 NuvaRing
15 Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy Completed NCT00642980 Phase 4 Clindamycin;Placebo;Clindamycin
16 Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-controlled Trial Completed NCT01800825 Phase 4 Clindamycin;Placebo
17 Examining the Impact of Tampon Use on the Vaginal Microbiota Completed NCT03346759 Phase 4
18 Oral N-Acetyl Cysteine Can Prevent Preterm Labour in Multiparae With Previous Preterm Labour Completed NCT00568113 Phase 4 acetylcysteine in arm 1
19 A Comparative Open Labeled Clinical Study to Evaluate the Efficacy and Tolerability of Two Different Intravaginal Formulations Containing a Combination of Clindamycin and Clotrimazole in Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
20 An Open-Label, Randomized, Multicenter Trial to Evaluate Continuation Rates, Side Effects and Acceptability of NuvaRing Versus OrthoEvra Completed NCT00269620 Phase 4 ethinyl estradiol/etonogestrel vaginal ring;ethinyl estradiol/norelgestromin transdermal contraceptive
21 A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis Recruiting NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
22 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
23 The Efficacy and Safety Study of Honghe Fujie Lotion for the Treatment of Bacterial Vaginosis Recruiting NCT03446443 Phase 4 Honghe Fujie lotion;Metronidazole Suppositories
24 Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital Recruiting NCT03894813 Phase 4 "Probiotics" and "Metronidazole";Metronidazole Vaginal
25 A Multi-Center, Open-Label Study to Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g Oral Granules for the Treatment of Adolescent Girls With Bacterial Vaginosis Recruiting NCT03937869 Phase 4 Secnidazole
26 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
27 Postmenopausal Pessary Users: Estrogen Versus Trimosan Recruiting NCT03943823 Phase 4 Estrogen vaginal cream;Trimo-San vaginal gel
28 Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity Active, not recruiting NCT02432404 Phase 4 NuvaRing
29 The Use of Colposeptine in Bacterial Vaginosis. A Randomized, Controlled Study Terminated NCT01153958 Phase 4 Colposeptine;Metronidazole
30 Phase II Multicentered Randomized Open-label Study of Effectiveness and Safety of Lactofiltrum in Women With Bacterial Vaginosis Unknown status NCT01089348 Phase 2, Phase 3 Lactofiltrum + Metronidazole;Metronidazole
31 Phase III, Randomized, Double Blind, Parallel Groups, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of the Lactobacillus Vaccine Gynevac, in the Treatment of Bacterial Vaginosis Unknown status NCT02173184 Phase 3
32 Single Blind Randomized Study of Efficacy and Safety of Vaginal Cream With Association of Metronidazole, Nystatin and Dexamethasone in the Treatment of Bacterial and Fungal Vaginal Infections Unknown status NCT02186145 Phase 3 Association of metronidazole; nystatin and dexamethasone;Flagyl
33 Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Unknown status NCT00491270 Phase 3
34 VA-SENSE - BACTERIAL VAGINOSIS ONCE A WEEK SCREENING AND TREATMENT TO REDUCE INFECTIVE COMPLICATIONS, ABORTION AND PRETERM DELIVERY IN PREGNANT WOMEN WITH PREVIOUS PRETERM DELIVERY. Unknown status NCT01152528 Phase 3
35 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
36 The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial Unknown status NCT00536848 Phase 2, Phase 3 Metronidazole
37 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
38 Maternal Genitourinary Infections and Adverse Perinatal Outcomes in Sylhet District, Bangladesh Unknown status NCT01572532 Phase 3
39 A Phase III Randomized, Multi-center, Double-blind, Double-dummy, Placebo-controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets. Completed NCT00229216 Phase 3 Tinidazole
40 A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02418845 Phase 3 SYM-1219;Placebo
41 A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis Completed NCT01621399 Phase 3 Product 55394;Placebo Vehicle (non-treatment)
42 Phase III Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis Completed NCT01125410 Phase 3 Dequalinium chloride;Clindamycin
43 Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial Completed NCT01160796 Phase 3 placebo;Lcr35®
44 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577537 Phase 3 1% SPL7013 Gel;Placebo
45 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577238 Phase 3 1% SPL7013 Gel;Placebo
46 The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis Completed NCT01258556 Phase 2, Phase 3
47 A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
48 A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis Completed NCT03091777 Phase 3 GDC-229;Metronidazole Vaginal Gel 0.75%;Placebo
49 Intravaginal Treatment of Disturbances of Vaginal Flora Among HIV Infected and Uninfected Women in Malawi Completed NCT00140764 Phase 3 Metronidazole gel versus placebo gel
50 A Phase 3, Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02452866 Phase 3 SYM-1219

Search NIH Clinical Center for Bacterial Vaginosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acetic Acid
ACETIC ACID LIQUID
ACETIC ACID,GLACIAL LIQUID
CLINDAMYCIN PHOSPHATE PWDR
Metronidazole
Metronidazole Hydrochloride
METRONIDAZOLE PWDR
Povidone

Cochrane evidence based reviews: vaginosis, bacterial

Genetic Tests for Bacterial Vaginosis

Anatomical Context for Bacterial Vaginosis

MalaCards organs/tissues related to Bacterial Vaginosis:

40
Testes, Colon, Bone, Cervix, Eye, Liver, Skin

Publications for Bacterial Vaginosis

Articles related to Bacterial Vaginosis:

(show top 50) (show all 3756)
# Title Authors PMID Year
1
Effect of clindamycin treatment on vaginal inflammatory markers in pregnant women with bacterial vaginosis and a positive fetal fibronectin test. 54 61
19647824 2009
2
[Benefits of Affirm VPIII and L-PAP in the diagnosis of bacterial vaginosis]. 54 61
18588815 2008
3
Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. 54 61
18462081 2008
4
MBL2 genetic screening in patients with recurrent vaginal infections. 54 61
18211540 2008
5
Among pregnant women with bacterial vaginosis, the hydrolytic enzymes sialidase and prolidase are positively associated with interleukin-1beta. 54 61
17714681 2008
6
The role of mannose-binding lectin gene polymorphisms in women with recurrent bacterial vaginosis. 54 61
17678865 2007
7
Cytokines, pregnancy, and bacterial vaginosis: comparison of levels of cervical cytokines in pregnant and nonpregnant women with bacterial vaginosis. 54 61
17922400 2007
8
Uterine cervical inflammatory cytokines, interleukin-6 and -8, as predictors of miscarriage in recurrent cases. 54 61
17845205 2007
9
Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. 54 61
17470593 2007
10
Association of interleukin-1beta and interleukin-1 receptor antagonist polymorphisms with bacterial vaginosis in non-pregnant Italian women. 54 61
17314118 2007
11
Genital tract interleukin-8 but not interleukin-1beta or interleukin-6 concentration is associated with bacterial vaginosis and its clearance in HIV-infected and HIV-uninfected women. 54 61
18273408 2007
12
Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. 54 61
16988245 2006
13
Cervical inflammatory cytokines and other markers in the cervical mucus of pregnant women with lower genital tract infection. 54 61
16307744 2006
14
IL-1beta, IL-6 and IL-8 levels in gyneco-obstetric infections. 54 61
16338780 2005
15
Genetic variation in the interleukin-8 gene promoter and vaginal concentrations of interleukin-8 are not associated with bacterial vaginosis during pregnancy. 54 61
16038986 2005
16
Secondary predictors of preterm labour. 54 61
15715594 2005
17
Association between vaginal 70-kd heat shock protein, interleukin-1 receptor antagonist, and microbial flora in mid trimester pregnant women. 54 61
15746691 2005
18
[Correlation between levels of selected cytokines in cervico-vaginal fluid of women with abnormal vaginal bacterial flora]. 54 61
16494210 2005
19
Does bacterial vaginosis alter the sensitivity of screening tests for Chlamydia trachomatis? An analysis of patient characteristics. 54 61
12869223 2003
20
Determination of immunoglobulin A against Gardnerella vaginalis hemolysin, sialidase, and prolidase activities in vaginal fluid: implications for adverse pregnancy outcomes. 54 61
12517887 2003
21
Interrelationships of interleukin-8 with interleukin-1beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. 54 61
12529421 2003
22
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora. 54 61
12388968 2002
23
Correlation of local interleukin-8 with immunoglobulin A against Gardnerella vaginalis hemolysin and with prolidase and sialidase levels in women with bacterial vaginosis. 54 61
12023767 2002
24
Correlation of local interleukin-1beta levels with specific IgA response against Gardnerella vaginalis cytolysin in women with bacterial vaginosis. 54 61
12148539 2002
25
Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. 54 61
11845812 2002
26
Vaginal indicators of amniotic fluid infection in preterm labor. 54 61
11165584 2001
27
The preterm prediction study: cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. 54 61
10739520 2000
28
Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis. 54 61
9815222 1998
29
IL-1beta, IL-6, TNFalpha, fetal fibronectin, and endotoxin in the lower genital tract of pregnant women with bacterial vaginosis. 54 61
9740515 1998
30
Interleukin-1alpha, interleukin-6 and interleukin-8 in cervico/vaginal secretion for screening of preterm birth in twin gestation. 54 61
9654172 1998
31
Evaluation of a fast test to identify the presence of proline aminopeptidase in women with bacterial vaginosis. 54 61
18476142 1997
32
Use of a lactoferrin assay in the differential diagnosis of female genital tract infections and implications for the pathophysiology of bacterial vaginosis. 54 61
8946639 1996
33
Correlation between the clinical diagnosis of bacterial vaginosis and the results of a proline aminopeptidase assay. 54 61
18475340 1994
34
Endotoxin and interleukin-1 alpha in the cervical mucus and vaginal fluid of pregnant women with bacterial vaginosis. 54 61
8238178 1993
35
Diagnostic microbiology of bacterial vaginosis. 54 61
8357044 1993
36
Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. 54 61
1551983 1992
37
Is trichomoniasis often associated with bacterial vaginosis in pregnant adolescents? 54 61
1372472 1992
38
A new proline aminopeptidase assay for diagnosis of bacterial vaginosis. 54 61
1892204 1991
39
Terconazole for the treatment of vulvovaginal candidiasis. 54 61
2277372 1990
40
An Assessment of Risk Factors for Herpes Simplex Virus Type 2 Infection in Malawian Women Using 2 Classifications for the HerpeSelect 2 Test. 61
31876866 2020
41
A Rare Cause of a Scrotal Abscess due to the Symbiotic Infection of Gardnerella vaginalis and Prevotella bivia in an Adult Male. 61
32024139 2020
42
Multimodality Screening for Lower Genital Tract Infections Between 18 and 24 Weeks of Pregnancy and its Efficacy in Predicting Spontaneous Preterm Delivery. 61
32030004 2020
43
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis. 61
31812702 2020
44
Apoptosis of vaginal epithelial cells in clinical samples from women with diagnosed bacterial vaginosis. 61
32029862 2020
45
Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis. 61
31789672 2020
46
Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure. 61
31404542 2020
47
An interpretation algorithm for molecular diagnosis of bacterial vaginosis in a maternity hospital using machine learning: proof-of-concept study. 61
31836253 2020
48
Intrauterine Foley catheter for 48 versus 24 hours for cervical ripening: A randomized controlled trial. 61
32010972 2020
49
Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis infections in low-risk women, St. Petersburg, Russia. 61
32036466 2020
50
Nonoptimal Vaginal Microbiota After Azithromycin Treatment for Chlamydia trachomatis Infection. 61
31573603 2020

Variations for Bacterial Vaginosis

Expression for Bacterial Vaginosis

Search GEO for disease gene expression data for Bacterial Vaginosis.

Pathways for Bacterial Vaginosis

Pathways related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TNF TLR9 TLR4 TLR2 PI3 NEU1
2
Show member pathways
13.5 TNF TLR9 TLR4 TLR2 IL6 IL1B
3
Show member pathways
13.23 TNF TLR9 TLR4 TLR2 MBL2 IL6
4
Show member pathways
13 TNF TLR4 TLR2 IL6 IL1B CXCL8
5
Show member pathways
12.96 TNF PRF1 IL6 IL1B IL1A IL10
6
Show member pathways
12.91 TNF TLR9 TLR4 TLR2 IL6 IL1B
7 12.83 TNF TLR9 TLR2 IL6 IL1B
8
Show member pathways
12.82 TNF TLR9 TLR4 TLR2 IL6 IL1B
9
Show member pathways
12.8 TNF TLR4 IL6 IL1B CXCL8
10
Show member pathways
12.71 TNF TLR4 TLR2 IL6 IL1B IL1A
11
Show member pathways
12.7 TNF TLR9 TLR4 TLR2 IL6 IL1B
12
Show member pathways
12.69 TNF TLR9 TLR4 TLR2 IL1B IL1A
13 12.63 TNF TLR9 TLR2 IL1B IL10
14
Show member pathways
12.46 TNF TLR2 IL6 IL1B DEFB4A CXCL8
15
Show member pathways
12.46 TLR2 PI3 LTF DEFB4A DEFA5 DEFA1
16
Show member pathways
12.44 TNF TLR4 IL6 IL1B IL1A CXCL8
17 12.41 TNF TLR4 IL1B CXCL8
18 12.4 TNF TLR4 IL6 IL1B CXCL8
19
Show member pathways
12.39 TNF TLR4 TLR2 IL1B IL1A IL10
20
Show member pathways
12.38 TNF IL6 IL1B IL1A IL10 CXCL8
21
Show member pathways
12.37 TNF IL6 IL10 CXCL8
22
Show member pathways
12.36 TNF TLR9 TLR4 TLR2 IL6 IL1A
23
Show member pathways
12.34 TNF TLR2 IL6 IL1B IL1A CXCL8
24
Show member pathways
12.33 TNF TLR9 IL6 IL1B IL10
25 12.3 TNF TLR9 TLR4 TLR2 IL6
26 12.29 TNF IL6 IL1B IL1A IL10 CXCL8
27
Show member pathways
12.27 TNF TLR4 IL1B IL1A
28 12.26 TNF TLR4 IL6 IL1B DEFB4A DEFA5
29 12.23 TNF TLR9 TLR4 TLR2 IL6 IL1B
30
Show member pathways
12.17 TNF TLR4 TLR2 IL6 IL1B
31
Show member pathways
12.16 TLR9 TLR4 TLR2 IL1B IL1A
32
Show member pathways
12.15 TNF TLR9 TLR4 TLR2 IL6 IL1B
33 12.14 TNF TLR4 IL6 IL1B IL10 CXCL8
34 12.13 TNF TLR4 IL6 IL1B IL1A CXCL8
35 12.1 TNF IL6 IL1B IL1A IL10 CXCL8
36
Show member pathways
12.08 TNF TLR9 TLR4 TLR2 IL6 IL1B
37 12.05 TNF IL6 IL1B IL1A CXCL8
38 12.04 IL6 IL1B IL1A CXCL8
39 12.02 TNF TLR4 IL1B CXCL8
40 12.02 MBL2 IL10 DEFB4A DEFA5 DEFA1
41 12 TNF IL6 IL1B IL1A
42 11.99 TNF TLR4 TLR2 IL6 IL1B IL10
43 11.92 TLR4 IL6 IL1B IL1A CXCL8
44 11.88 TNF TLR9 IL6 IL1B IL10
45 11.85 TLR9 TLR4 TLR2
46 11.85 TNF IL6 IL1B IL10
47 11.83 TNF TLR4 TLR2 IL6 IL1B IL1A
48 11.82 TNF IL1B IL10
49 11.79 TNF IL6 IL1B CXCL8
50
Show member pathways
11.79 TNF IL6 IL1B IL1A CXCL8

GO Terms for Bacterial Vaginosis

Cellular components related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.73 TLR9 TLR2 PRF1 NEU1 IL1B DEFA5
2 extracellular space GO:0005615 9.73 TNF MMP8 MBL2 LTF IL6 IL1B
3 extracellular region GO:0005576 9.53 TNF TLR9 PRF1 PI3 NEU1 MMP8
4 specific granule lumen GO:0035580 9.33 NEU1 MMP8 LTF

Biological processes related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.28 TNF TLR9 TLR4 TLR2 IL6 IL1B
2 positive regulation of gene expression GO:0010628 10.16 TNF TLR9 TLR4 TLR2 MMP8 IL6
3 neutrophil degranulation GO:0043312 10.15 TLR2 NEU1 MMP8 LTF DEFA1
4 negative regulation of cell proliferation GO:0008285 10.14 TLR2 IL6 IL1B IL1A IL10 CXCL8
5 cytokine-mediated signaling pathway GO:0019221 10.1 TNF IL6 IL1B IL1A IL10 CXCL8
6 inflammatory response GO:0006954 10.09 TNF TLR9 TLR4 TLR2 IL6 IL1B
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.05 TNF TLR9 TLR4 LTF IL1B IL1A
8 defense response to virus GO:0051607 10.04 TLR9 PRF1 IL6 DEFA1
9 defense response GO:0006952 10.04 TNF DEFB4A DEFA5 DEFA1 CXCL8
10 response to lipopolysaccharide GO:0032496 10.03 TLR4 TLR2 IL1B IL10
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.02 TNF TLR9 TLR4 TLR2 LTF IL6
12 positive regulation of DNA-binding transcription factor activity GO:0051091 9.99 TNF IL6 IL1B IL10
13 positive regulation of JNK cascade GO:0046330 9.99 TNF TLR9 TLR4 MMP8 IL1B IL1A
14 positive regulation of inflammatory response GO:0050729 9.98 TNF TLR9 TLR4 TLR2 IL1B
15 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.97 LTF DEFB4A DEFA5 DEFA1 CXCL8
16 antimicrobial humoral response GO:0019730 9.95 PI3 LTF DEFB4A DEFA5 DEFA1
17 neutrophil chemotaxis GO:0030593 9.93 IL1B IL1A CXCL8
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.93 TNF TLR9 TLR4 TLR2 MMP8 IL1B
19 response to glucocorticoid GO:0051384 9.92 TNF IL6 IL10
20 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.92 TNF TLR9 TLR4
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.92 TNF TLR4 MMP8 IL1B
22 humoral immune response GO:0006959 9.91 TNF LTF IL6
23 positive regulation of tumor necrosis factor production GO:0032760 9.91 TLR9 TLR4 TLR2
24 killing of cells of other organism GO:0031640 9.91 LTF DEFB4A DEFA5 DEFA1
25 negative regulation of interleukin-6 production GO:0032715 9.91 TNF TLR9 TLR4 IL10
26 defense response to Gram-positive bacterium GO:0050830 9.91 TNF TLR2 MBL2 IL6 DEFB4A DEFA5
27 defense response to bacterium GO:0042742 9.91 TNF TLR9 TLR4 MBL2 LTF IL10
28 positive regulation of phagocytosis GO:0050766 9.9 TNF MBL2 IL1B
29 positive regulation of interferon-gamma production GO:0032729 9.9 TNF TLR4 IL1B
30 positive regulation of interleukin-6 secretion GO:2000778 9.9 TNF TLR4 TLR2 IL1B
31 immune response GO:0006955 9.9 TNF TLR9 TLR4 TLR2 IL6 IL1B
32 toll-like receptor signaling pathway GO:0002224 9.89 TLR9 TLR4 TLR2
33 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.89 TNF IL1B IL1A
34 lipopolysaccharide-mediated signaling pathway GO:0031663 9.89 TNF TLR4 TLR2 IL1B
35 positive regulation of interleukin-8 production GO:0032757 9.89 TNF TLR9 TLR4 TLR2 IL1B
36 antibacterial humoral response GO:0019731 9.88 LTF DEFA5 DEFA1
37 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.87 TLR9 TLR4 TLR2
38 positive regulation of JAK-STAT cascade GO:0046427 9.87 TNF IL6 IL10
39 positive regulation of cytokine secretion GO:0050715 9.87 TNF IL1A IL10
40 defense response to Gram-negative bacterium GO:0050829 9.87 TLR9 TLR4 LTF IL6 DEFB4A DEFA5
41 positive regulation of vascular endothelial growth factor production GO:0010575 9.86 IL6 IL1B IL1A
42 negative regulation of neurogenesis GO:0050768 9.86 TNF IL6 IL1B
43 positive regulation of interleukin-12 production GO:0032735 9.85 TLR9 TLR4 TLR2
44 positive regulation of interferon-beta production GO:0032728 9.85 TLR9 TLR4 TLR2
45 positive regulation of interleukin-10 production GO:0032733 9.84 TLR9 TLR4 TLR2
46 innate immune response in mucosa GO:0002227 9.84 LTF DEFA5 DEFA1
47 positive regulation of neuroinflammatory response GO:0150078 9.84 TNF MMP8 IL6 IL1B
48 positive regulation of glial cell proliferation GO:0060252 9.83 TNF IL6 IL1B
49 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.83 TNF IL1B IL10
50 response to molecule of bacterial origin GO:0002237 9.83 TLR9 TLR2 IL10 CXCL8

Molecular functions related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 9.33 TLR4 TLR2 LTF
2 signaling pattern recognition receptor activity GO:0008329 9.32 TLR9 TLR2
3 lipopolysaccharide receptor activity GO:0001875 9.26 TLR4 TLR2
4 interleukin-1 receptor binding GO:0005149 9.13 TLR9 IL1B IL1A
5 cytokine activity GO:0005125 9.1 TNF IL6 IL1B IL1A IL10 CXCL8

Sources for Bacterial Vaginosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....